DFDena Firouzabadi

Dena Firouzabadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dena Firouzabadi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Clinical Value of Inflammatory Indicators at the Time of Secondary Infection After Treatment With Tocilizumab: A Cross‐Sectional Study

    by Dena Firouzabadi, Amirreza Dehghanian, Saeed DehghanKhalili, Seyed Mohammad Hosseini Saadi

    Background and Aims: Tocilizumab, an anti‐inflammatory agent used in severe COVID‐19 infection, is known to inhibit the Interleukin 6 receptor and reduce C‐reactive protein (CRP) resulting in an increased risk of secondary infections. However, the trend of secondary infection and the relative inflammatory response after tocilizumab use has been reported variably.Methods: In this observational cross‐sectional study, the time to normalization of CRP, rate of secondary infections, significance of infection indicators (CRP and white blood cell (WBC) count) at the time of secondary infections, length of intensive care unit (ICU) stay, and survival rate were evaluated in patients with severe COVID‐19 infection after tocilizumab use.Results: A total of 216 patients (118 tocilizumab receivers vs. 98 nonreceivers) were included in this study. A higher rate of blood‐stream infection (p 0.02), shorter ICU stay (p < 0.001) regardless of tocilizumab dose, and a slower rate of CRP normalization (p 0.009) were observed for tocilizumab receivers. The survival rate was not different between the two groups. A rise in CRP level was absent for tocilizumab receivers (p < 0.001) at the time of developing a secondary infection, while elevated WBC count was evident for both groups without any significant difference.Conclusion: Tocilizumab can increase the risk of secondary infections, while CRP levels may remain suppressed at the time. Therefore, CRP may not be suggested as a reliable marker of infection in tocilizumab users, although WBC count may remain a consistent value in confirming secondary infections in this population.


  • Open Access

    Effect of Melatonin on Oxaliplatin Induced Neuropathy in Patients Receiving Folfox Chemotherapy Regimens for Stage II–IV Colorectal Cancer: A Randomized, Placebo Controlled, Double Blind Trial

    by Raziyeh Kheshti, Mehdi Dehghani, Soha Namazi, Dena Firouzabadi, Laleh Mahmoudi, Elham Haem

    Background and Aims: Peripheral neuropathy is a major side effect of oxaliplatin‐based chemotherapy. The aim of this placebo‐controlled double‐blind randomized study was to evaluate the effect of melatonin on prevention of oxaliplatin induced peripheral neuropathy (OXIPN) in patients receiving oxaliplatin for colorectal cancer. Methods: Patients with stage II–IV colorectal cancer, who were to receive oxaliplatin‐based chemotherapy, were enrolled according to the inclusion criteria and randomly assigned to take either melatonin (20 mg/day) or placebo, during chemotherapy and 1 month after. Neuropathy was assessed by several patient‐ and physician‐based reports, including the National Cancer Institute Common Terminology Criteria for Adverse Events scale (NCI‐CTCAE), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy‐Induced Peripheral Neuropathy 20 (EORTC QLQ‐CIPN20) scale, and oxaliplatin specific scale (OSS). Results: From a total of 80 selected patients, 54 completed the study and were evaluated for the final analysis. Grade 3 neuropathy measured by NCI‐CTCAE and OSS in the melatonin arm was significantly lower than the placebo group. But according to EORTC QLQ‐CIPN20 scale, no statistically significant difference was observed between the groups. In addition, melatonin use did not improve patients' quality of life compared with placebo. Conclusion: Reduction in grade 3 neuropathy based on NCI‐CTCAE and OSS can be of great importance, as it is the higher‐grade neuropathy that may lead to functional impairment. Given that to date no medication has been approved for prevention of OXIPN and considering the limited number of patients in the present study, conducting a larger clinical trial on the effect of melatonin may lead to beneficial results in this group of patients. Trial Registration: Study registered (Date: 23 July, 2018) in the Iranian Registry of Clinical Trials (IRCT); IRCT20170326033139N1 ( https://www.irct.ir/search/result?query=IRCT20170326033139N1 )


  • Open Access

    Health-Related Quality of Life (HRQoL) in COVID-19 Patients After Recovering from the Acute Infection

    by Dena Firouzabadi, Laleh Mahmoudi, Maryam Kadkhodamohammadi, Ramin Niknam, Ali Amanati

    Background: Nearly four years after the COVID-19 outbreak, its burden persists, with long-term physical and mental impacts still being discovered. Objectives: Given that these effects may vary across different periods post-infection and in diverse cultural, medical, and economic settings, we aimed to evaluate the health-related quality of life (HRQoL) in Iranian patients six months after acute infection. Methods: A total of 194 infected patients were enrolled and re-evaluated six months after the onset of acute infection. Health-related quality of life was assessed using the validated EQ-5D-3L questionnaire. Results: The mean age of patients was 50.1 ± 15.8 years, with a female-to-male ratio of 1.04. Diabetes mellitus and hypertension were the most common comorbidities. Significant impairment was observed in all categories of HRQoL after recovery from acute COVID-19 infection (P-value < 0.05). Female gender, older age, and intensive care unit admissions were independent factors associated with worsened health status post-recovery. The overall reduction in post-COVID-19 infection quality of life (QoL) score was 25%. Conclusions: The mental and physical burden of COVID-19 in our study population was considerable. Comorbid conditions and a lack of supportive measures post-infection, especially in a low-income country, may contribute to the long-term effects of COVID-19.


  • Cancer-Related Malnutrition and the Role of Parenteral Nutrition in Cancer; A Narrative Review

    by Dena Firouzabadi, Hossein Ahmadi

    The growing incidence rate of cancer and its associated morbidity and mortality prompts the need to identify factors that could improve the quality of life (QoL) and survival of a patient with cancer. Cancer-associated malnutrition is a common complication that could start at the early stages of cancer and could further develop into advanced cachexia. Response to treatment, length of hospital stay, progression of infection, and other complications of cancer including chemotherapy adverse events could all be influenced by the progression of malnutrition. Nutritional interventions may vary from oral to enteral and parenteral therapy. Parenteral nutrition (PN) therapy may benefit patients at certain stages of cancer in whom contraindications or inefficacy of other modalities of nutritional support are present. This method may seem invasive, costly, and risky but at the same time may improve certain patients' QoL and chance of survival. In trained settings with proper facilities, this method of nutritional support can benefit patients; However, the indication for starting PN must be carefully supervised considering that other nutritional support methods may be equally efficient and at the same time easier to access and apply.


  • Open Access

    The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID‐19 patients: A systematic review and meta‐analysis

    by Dena Firouzabadi, Fatemeh Kheshti, Saeed Abdollahifard, Erfan Taherifard, Mohammad Reza Kheshti

    Background and Aim: Due to the high social and economic burden and also mortality and morbidity caused by coronavirus disease 2019 (COVID‐19) in the past few years, researchers have aimed at finding solutions to suppressing the severity of infection. Recently, selective serotonin and serotonin‐norepinephrine reuptake inhibitors (SSRI/SNRI) have been investigated as an adjuvant treatment for COVID‐19. The aim of the current study was to investigate the impact of SSRI/SNRIs on outcomes of COVID‐19 patients.Methods: In this systematic review and meta‐analysis, a comprehensive search strategy consisting of relevant words was performed by two researchers in PubMed, Scopus and EMBASE libraries. Studies reporting the effect of SSRI and/or SNRI use in COVID‐19 patients' outcome were included. Hospitalization, mortality, hospitalization event, and length of hospital stay were considered as main outcomes of this study. Analysis was carried out using Comprehensive Meta‐Analysis (CMA‐version 2) and final data were reported as odds ratio (OR) and 95% confidence interval (CI).Results: Our search led to the final selection of 9 articles including 15,287 patients. The effect of fluvoxamine, fluoxetine, and the overall effect of SSRI/SNRI use on mortality of COVID‐19 patients were investigated in 3, 2, and 7 articles, respectively. The results of our analyses showed that these medications could significantly decrease mortality of COVID‐19 patients (OR and 95% [CI]: 0.595 [0.467–0.758], 0.620 [0.469–0.821], and 0.596 [0.437–0.813]). The effect of SSRI/SNRIs on hospitalization events of COVID‐19 patients was not significant (OR: 0.240% and 95% CI: 0.041–1.4). Also, length of hospital stay was longer in patients who administrated SSRIs.Conclusion: According to this study's results, SSRI/SNRIs may be effective in reducing mortality of COVID‐19 patients, suggesting the superiority of fluvoxamine to fluoxetine. The safety profile and affordable cost of SSRI/SNRIs for a short‐term use may be other reasons to propose them as beneficial medications in preventing mortality in COVID‐19.


  • Open Access

    Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

    by Dena Firouzabadi, Amirreza Dehghanian, Alireza Rezvani, Laleh Mahmoudi, Abdolrasoul Talei

    Background: Neoadjuvant chemotherapy (NACT) is the prime approach to the management of locally advanced breast cancer (LABC). Influenced by different factors such as pathologic tumor characteristics, hormone receptor status, HER2 and proliferation marker expressions, response to therapy cannot be easily predicted. Pathologic complete response (pCR) has been considered as an endpoint to NACT; however, pCR rates have been unsatisfactory in such patients. In this randomized trial, we studied the efficacy of carboplatin/gemcitabine as second-line NACT while evaluating the impact of different factors affecting response.Methods: In this randomized controlled trial, 52 clinically non-responsive (confirmed by palpation and/or ultrasonography) LABC patients to 4 cycles of doxorubicin/cyclophosphamide followed by 4 cycles of paclitaxel ± trastuzumab were randomly allocated to two groups. “Control” group underwent breast surgery and were further evaluated for pCR (ypT0/is ypN0). “Intervention” group received 2 cycles of carboplatin/gemcitabine and patients were further evaluated for pCR following surgery.Results: In a total of 52 patients, pCR rate was 30.7%. pCR and response rate in lymph nodes were higher in carboplatin/gemcitabine recipients (32% vs 29.7 and 44% vs 40.7% respectively), however differences were insignificant. In both the “intervention” group and total study population, most pCR cases were of the hormone receptor (HR)+/HER2+ subtype (87.5% and 75% respectively). HER2 positivity, ki67 expression, lower extent of ER positivity, higher tumor grade and tumor-infiltrating lymphocyte (TIL) lead to higher pCR rates. Adverse events following addition of carboplatin/gemcitabine were mostly hematologic and none required hospitalization. Anemia was the most common grade 3 adverse event observed. No grade 4 toxicity was evident.Conclusion: Although the proposed carboplatin/gemcitabine combination could not improve pCR rates as expected, probability of immune activation following use of carboplatin in achieving response to NACT may be considered. Accounting for the highest number of pCR cases in the “intervention” group, the HR+/HER2+ subtype with high TILs may be considered as most responsive to the proposed regimen in this study. It is noteworthy that the proposed combination imposed minimal toxicity.Trial registration: This trial was prospectively registered in IRCT.ir (IRCT2017100136491N1). Date of registration: 19 November 2017.


  • Open Access

    The Impact of an Antibiotic Stewardship Program on the Consumption of Specific Antimicrobials and Their Cost Burden: A Hospital-wide Intervention

    by Laleh Mahmoudi, Alireza Sepasian, Dena Firouzabadi, Ali Akbari

    Background: Inappropriate use of antimicrobials (AM) is a major concern worldwide that leads to the propagation of antimicrobial resistance (AMR). In addition to its clinical implications, AMR imposes an economic burden on communities, especially developing countries with more infectious diseases and less available resources. Antimicrobial stewardship programs (ASPs) have been found to be effective in reducing AMR. This study was designed to evaluate the effect of implementing an ASP in reducing AM consumption, its economic burden, and AMR as a consecutive result. Materials and Methods: Consumption of caspofungin, amphotericin B, voriconazole, colistin, linezolid, vancomycin, and carbapenems was compared in a prospective cross-sectional study between two time periods introduced as pre- and post-ASP. Drug use density presented as anatomical therapeutic chemical (ATC)/defined daily doses (DDD) and normalized per 1000 bed days, cost savings, and AMR patterns were evaluated. Results: A total of 9400 AM prescriptions were analyzed during a 2-year period. Consumption measured in DDD/1000 bed days dropped by 24.8, 25.0, 35.3, 47.0, 39.2, 10.5, and 23.2 percent for amphotericin B, caspofungin, colistin, voriconazole, meropenem, imipenem, and vancomycin, respectively. Linezolid consumption increased by 26.8% after implementing ASP. The expenditure of target AMs in the average value of USD decreased by 41.3% after the intervention compared to the time before using ASP (P-value=0.001). Implementing ASP also increased AM susceptibility of Pseudomonas aeruginosa, while the susceptibility of methicillin-resistant Staphylococcus aureus did not change significantly. Conclusion: The results of this study suggest that establishment of ASP can lead to a reduction in improper administration of AMs and their expenditure resulting in economic benefit and lowering AMR at hospitals with minimum resources. Clinical pharmacists’ role was critical to the success of this ASP and was uniquely empowered at our center.


  • Open Access

    Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran

    by Dena Firouzabadi, Alireza Rezvani, Amirreza Dehghanian, Laleh Mahmoudi

    Purpose: Heterogeneity of breast cancer, the most common cancer in women, complicates approach to its treatment. Neoadjuvant chemotherapy (NAC) in the treatment of locally advanced breast cancer (LABC) with the endpoint of achieving pathologic complete response (pCR) is not always successful. The purpose of this study was to evaluate the clinicopathologic characteristics, biomarker status and response of LABCs to NAC. Patients and methods: Core biopsies and post-surgical specimens of LABC patients were evaluated after receiving NAC. Their lymph node involvement, tumor staging, grading, size, tumoral and stromal lymphocytic infiltration (TLI, SLI), hormonal status, ki67, p53 and HER2 expression were evaluated. Response to NAC was assessed using pCR, Miller-Payne grading and residual cancer burden. Results: In a total of 71 patients, pCR rate was 5.6%. Strong association was observed between ki67 positivity and p53 expression (P-value˂0.001). Also ki67, TLI and SLI showed association with triple negative tumor subtype (P-value 0.011, 0.002 and 0.014). Good response to NAC was associated with p53 expression. Nodal metastatic residue was also associated with primary tumor’s nuclear grade. Conclusion: Strong correlation of ki67 and p53 can suggest probable interchangeability of both markers in the prognosis of LABC. In this study p53 even showed superiority to ki67 having association with good response. Strong association of ki67, TLI and SLI with triple negative tumor subtype can be parallel to an overall better response rate of this subtype. We can also propose the effectiveness of defining nuclear grade as a prognostic factor towards residual lymph node involvement post NAC.


  • Knowledge, attitude, and practice of health care workers towards antibiotic resistance and antimicrobial stewardship programmes: A cross‐sectional study

    by Dena Firouzabadi, Laleh Mahmoudi

    Rationale and Aims: Antibiotic development was a major breakthrough in defeating infections; however, their vast use has led to antimicrobial resistance (AMR) causing mortality, morbidity, and financial burden worldwide. Considering the limited introduction of newer antimicrobials to overcome resistance patterns, sufficient knowledge of their use can help manage this issue. Antimicrobial stewardship programmes (ASPs) with the mainstay of education can be a good resolution. The aim of this study was to seek aspects in which knowledge regarding antibiotics is lacking at our institutions.Materials and Methods: This cross‐sectional study performed in Shiraz, South of Iran, was designed as a knowledge, attitude, and practice (KAP) study. A self‐administered questionnaire consisting of 15 questions was designed and handed out to health care workers including infectious disease practitioners, surgeons, internal medicine specialists and residents, general practitioners, medical students, and microbiology lab technicians and PhD graduates. Difference in response to questions was evaluated between the practitioner and nonpractitioner groups.Results: Completed questionnaires were collected (n = 126). According to the results, most participants (88.1%) agreed on establishment of local guidelines. Majority (94.4%) also believed that education regarding antibiotics can help reduce AMR. Good patient care was not believed to be impaired by limiting use of antibiotics (72.2%). A significant difference in the practitioner and nonpractitioner groups' practice score was observed.Conclusion: In our study, knowledge deficit was observed in some aspects of AMR. We can conclude that more practice and education are needed in ASP for the better performance in reducing resistant patterns.